Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Werewolf Therapeutics (Nasdaq: HOWL) will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9-10, 2022.

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9-10, 2022. The company focuses on developing conditionally activated therapeutics to enhance the immune system for cancer treatment. Utilizing its proprietary PREDATOR™ platform, Werewolf aims to create molecules that activate selectively within the tumor microenvironment, minimizing side effects. Key product candidates include WTX-124 and WTX-330, both targeting solid tumors and designed to work with immune checkpoint inhibitors. For more information, visit www.werewolftx.com.

Argus Session date unavailable

-0.62% session move Open Argus

Details

News Market Reaction – HOWL

The recorded move for HOWL in the trading session of this news was -0.62%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
josh.rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date of the 2022 Wedbush PacGrow Healthcare Virtual Conference for Werewolf Therapeutics?

Werewolf Therapeutics will participate in the conference on August 9-10, 2022.

What is Werewolf Therapeutics known for?

Werewolf Therapeutics specializes in developing conditionally activated therapeutics that stimulate the immune system to combat cancer.

What are the main product candidates of Werewolf Therapeutics?

The main product candidates are WTX-124 and WTX-330, targeting solid tumors with conditionally activated Interleukin-2 and Interleukin-12.

What platform does Werewolf Therapeutics use for its drug development?

Werewolf Therapeutics uses the proprietary PREDATOR™ platform for developing its therapeutics.

How do WTX-124 and WTX-330 function?

WTX-124 and WTX-330 remain inactive in peripheral tissue but activate selectively in the tumor microenvironment.